For many patients, getting a diagnostic result still means travelling to a laboratory equipped with specialised machines and infrastructure. Vidcare, co-founded by Rohan Aggarwal and Dr. Saurabh Kumar Srivastava, is developing Mu-Sure, a diagnostic platform built on its proprietary Volume Amplification Measurement (VAM) technology. Its disposable, zero-electronics test kits are designed for professional use at the point of care and provide quantitative results in around 20 minutes. The company is initially developing tests for thyroid-stimulating hormone (TSH) and HbA1c, a marker used in diabetes care. Its goal is to make useful diagnostic information available closer to the patient, while pursuing the regulatory approvals and clinical evidence required for medical use.
A More Accessible Diagnostic Experience
Rohan’s ambition is to build an intellectual-property-driven company that can contribute to better healthcare globally. He saw an opportunity to rethink tests that typically depend on laboratory equipment and dedicated infrastructure. Vidcare’s test kits are designed to work without electronic analysers. They use disposable cartridges and are intended to deliver numerical results in approximately 20 minutes. “The aim is to reduce the infrastructure and equipment needed to get a quantitative result, and make testing more accessible.”
The distinction between a quantitative result and a simple positive-or-negative reading matters for conditions where clinicians need a numerical value to guide decisions. Vidcare’s intended model is to give doctors useful test information closer to the point of care, potentially reducing friction in the patient journey.
Why Vidcare?
The name Vidcare brings together two ideas: care for patients and vidya, meaning knowledge or learning. It reflects the company’s focus on combining medical care with research and technical innovation. For Rohan, the company’s purpose is not only to develop a product, but to create a technology platform that can address diagnostic-access challenges in India and potentially other markets.
Starting with Thyroid and Diabetes Testing
Vidcare’s first two tests focus on TSH and HbA1c. The team selected these areas because thyroid conditions and diabetes are significant health concerns in India, and both require more than a basic yes-or-no result. A numerical measurement can be important to clinical assessment and ongoing care. The company believes its initial focus addresses needs that may receive less attention from diagnostic technologies developed primarily for Western markets. The product is designed to support clinical decision-making, not replace it. As a medical device company, Vidcare is working through the regulatory process before commercial distribution.
Eight Years of Research and Development
Developing a disposable cartridge that can produce a quantitative result without electronics has been a major technical challenge. The product needed to replicate functions typically performed by a laboratory machine while remaining usable without an electronic analyser.
The company has spent approximately eight years on research and development. Moving from laboratory prototypes to repeatable commercial-scale production also required the team to design custom semi-automated manufacturing equipment. The work involves more than developing the test chemistry. Vidcare must also establish reliable production processes, demonstrate consistent performance, and help clinicians and patients understand how the technology differs from conventional laboratory and rapid tests.
Building the Evidence for Trust
In healthcare, product claims must be supported by evidence. Vidcare is conducting clinical evaluations that compare its tests with established laboratory methods. The company plans to expand validation across different patient groups and settings, including pregnant populations, rural and field environments, varied clinical contexts, and patients using different medications. It also intends to publish peer-reviewed evidence. “Trust has to come from clinical evaluation and evidence not just from how a product is described.” Making clinical data available to clinicians will be an important step in helping them assess the technology. The company’s current priority is to complete regulatory and validation work before moving into wider manufacturing and distribution.
Funding Research and Intellectual Property
Vidcare began lean, relying on founder savings, government grants, and incubation support. Much of the early capital went towards research and development and protecting its core invention with granted intellectual property in major markets including India, the United States, Europe, China, Japan, and Brazil. The company’s first major equity round was led by Social Alpha, with participation from Lavni Ventures and Derbi Foundation. A later bridge round was led by Lavni Ventures with participation from LetsVenture, FAAD Network and angel investors. This funding has supported the shift from early discovery towards validation, manufacturing readiness, and the generation of clinical evidence.
From Discovery to Deployment
Vidcare’s next phase is focused on proving that its technology works consistently in real clinical conditions and can be manufactured reliably. The company must complete the necessary regulatory steps, strengthen its production capability, and build confidence among doctors and patients. For Rohan, making diagnostics more accessible requires both technical innovation and a disciplined process for demonstrating safety and performance. A test that is faster or easier to access must still meet the standards expected of a medical tool.
A Broader Healthcare Ambition
Vidcare’s longer-term ambition is to create diagnostic tools that can deliver useful results without depending on large machines or centralised laboratory infrastructure. If validated and approved, such tools could help bring testing closer to patients and support more timely clinical decisions. The company’s immediate focus remains on its TSH and HbA1c kits, regulatory approval, manufacturing readiness, and clinical validation. Its broader vision is to build an IP-led diagnostics company that combines accessibility with quantitative performance and evidence-based use.
For Rohan Aggarwal and co-founder Dr. Saurabh Kumar Srivastava, the work is ultimately about making the diagnostic process more practical for patients and clinicians—while earning trust through rigorous testing, transparency, and clinical evidence.
Interview By: Sejal Thakur
